A sensitive and specific liquid chromatography–tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients
- 15 September 2010
- journal article
- Published by Elsevier in Journal of Chromatography B
- Vol. 878 (26) , 2409-2414
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Belinostat: a new broad acting antineoplastic histone deacetylase inhibitorExpert Opinion on Investigational Drugs, 2009
- Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assayInternational Journal of Colorectal Disease, 2008
- A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasiaEuropean Journal of Haematology, 2008
- Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancerInternational Journal of Cancer, 2007
- Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primatesCancer Chemotherapy and Pharmacology, 2007
- A Simple and Sensitive High-Performance Liquid Chromatographic Method for Quantification of PXD101, a Histone Deacetylase Inhibitor in Human PlasmaTherapeutic Drug Monitoring, 2007
- The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivoCancer Chemotherapy and Pharmacology, 2006
- A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasmaRapid Communications in Mass Spectrometry, 2003
- Strategies for the Assessment of Matrix Effect in Quantitative Bioanalytical Methods Based on HPLC−MS/MSAnalytical Chemistry, 2003
- Liquid chromatography/atmospheric pressure ionization–mass spectrometry in drug metabolism studiesJournal of Mass Spectrometry, 2003